MetaCap

Atossa Therapeutics (ATOS) vs Celularity (CELU)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Celularity (CELU) has outperformed Atossa Therapeutics (ATOS) over the past year, losing 73.5% versus a loss of 86.4%. Over five years, ATOS leads with a -95.3% price change compared with -99.3% for CELU. Atossa Therapeutics is the larger company by market cap ($15.9 million vs $15.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ATOS-86.37%CELU-73.54%
+25%-33%-92%
Nov 21, 20251 yearNov 20, 2026
ATOS-95.48%CELU-99.34%
+83%-12%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ATOS versus CELU key metrics
MetricATOSCELU
Share price$1.60$0.463
Market cap$15.92M$15.02M
1-day change-8.86%-1.05%
YTD return-81.98%-58.29%
1-year return-86.37%-73.54%
5-year return-95.34%-99.31%
EPS (TTM)$-3.92$-1.69
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$26.55M
Revenue growth (YoY)—-51.03%
Net income (latest FY)$-34.77M$-91.72M
Gross margin—24.39%
Operating margin—-230.92%
Net margin—-345.45%
52-week high$14.85$2.55
52-week low$1.59$0.42
Distance from 52-week high-89.26%-81.84%
Analyst consensusstrong_buy—
Avg. price target upside+1091.22%—
Average volume68.00K3.95M
Shares outstanding9.98M32.45M
Employees16115
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CELU has outperformed ATOS by 12.8 percentage points over the past year.

About Atossa Therapeutics

ATOS stock →

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas.

Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees

About Celularity

CELU stock →

Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking.

Health Care · Biotechnology: Pharmaceutical Preparations · 115 employees

ATOS vs CELU FAQ

Which is bigger, Atossa Therapeutics or Celularity?

Atossa Therapeutics (ATOS) is larger, with a market capitalization of $15.92M compared with $15.02M for Celularity (CELU).

Which stock has performed better over the past year, ATOS or CELU?

CELU returned -73.54% over the past 12 months, compared with -86.37% for ATOS (price return, excluding dividends). Past performance does not predict future results.

Are Atossa Therapeutics and Celularity in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons